Equity Research Insurance Brokers

Should You Buy Marsh Stock in 2026?

By CirclFi Research Team · · 13/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Marsh (MRSH) stands out as one of the highest-quality businesses in our coverage universe, earning a Quality of Company score of 9.3/10. At a current price of $182.18 and a market capitalization of $87.8B, the core investment question is whether the stock offers a compelling entry point relative to its estimated intrinsic value.

The short answer: 3 of 13 CirclFi valuation models project upside for Marsh (MRSH) at $182.18 — the model consensus leans bearish, with a Quality Score of 9.3/10 and Value-Trap risk of 12/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 10 of 13 models suggest overvaluation — majority bearish
  • Quality Score: 9.3/10 — Excellent — top-tier fundamentals
  • Value Trap Risk: 12/100 — Minimal — healthy fundamentals
  • Fair Value Range: $27.09 – $547.31 (1920% spread)

Bullish Models

3 / 13

Bearish Models

10 / 13

Quality Score

9.3 /10

Excellent — top-tier fundamentals

Value Trap Risk

12 /100
Minimal

Minimal — healthy fundamentals

Model Consensus

13 /13
Active Models

Avg. confidence: 48%

Investment Thesis

The Bull Case

Target: $547.31 (+200.4% upside)

  • According to the CirclFi Quality of Company (QOC) framework, Marsh's quality score of 9.3/10 demonstrates the operational excellence that historically correlates with long-term shareholder value creation.
  • According to the CirclFi Deep Alpha Valuation Engine, the Markov DDM model targets a fair value of $547.31 (+200.4%), anchoring the bull case with a methodology that provides a differentiated analytical lens.
  • Industry tailwind: underwriting discipline could provide meaningful support for Marsh's revenue and margin trajectory in the Insurance Brokers space.
  • Scale advantage: as a $87.8B large-cap company, Marsh benefits from economies of scale, institutional investor demand, and index inclusion that smaller competitors lack.

The Bear Case

Target: $27.09 (-85.1%)

  • According to the CirclFi Deep Alpha Valuation Engine, the Dynamic NAV model sees the stock as overvalued with a fair value of $27.09 (-85.1%), suggesting that the market price embeds overly optimistic growth assumptions.
  • According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +285.6% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology.
  • Industry headwind: reserve deficiency represents a meaningful risk for Marsh and its Insurance Brokers peers.

Peer Benchmarking

CRVL CorVel Corp.
9.9
ERIE Erie Indemnity Compa
9.7
BRO Brown & Brown, Inc.
9.3
AJG Arthur J. Gallagher
9.1
GSHD Goosehead Insurance,
8.8

Valuation Divergence

Spread

1920%

Fair Value Range

$27.09 – $547.31

A 1920% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

Markov DDM

$547.31 (+200.4%)

Most Bearish

Dynamic NAV

$27.09 (-85.1%)

Key Risk Factors

Model Disagreement

1920% spread signals high variance in projections.

Bearish Consensus

10/13 models suggest overvaluation.

Macro/Sector Risk

Insurance Brokers headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View MRSH Data Page →

The Bottom Line

Our valuation engine sends a clear cautionary signal on Marsh at $182.18. 10/13 models flag overvaluation, composite fair value sits at $154.91 (-15.0%), and the risk-reward profile appears unfavorable. Quality at 9.3/10 is the one bright spot, but premium quality at the wrong price can still destroy returns. This is a stock where patience — or avoidance — may be the optimal strategy.

These are quantitative model outputs, not investment recommendations. Marsh's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

Frequently Asked Questions

Should I buy MRSH stock right now?

Based on CirclFi's multi-model analysis, 3 of 13 models see upside for MRSH at $182.18. The models are divided, which means the investment case depends heavily on your assumptions about Marsh's future. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Marsh?

Key risks include: wide model disagreement (1920% spread), signaling high uncertainty; general market and sector-specific risks affecting Insurance Brokers companies. Always diversify and consult a financial advisor.

How does MRSH compare to its competitors?

Among Insurance Brokers peers, MRSH holds a Quality Score of 9.3/10. Comparable companies include CRVL (QOC 9.9), ERIE (QOC 9.7), BRO (QOC 9.3). The relative ranking helps investors identify whether MRSH offers better fundamental quality than alternatives in the same sector.

Is MRSH a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. MRSH's Quality Score of 9.3/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.

What price should I buy MRSH at?

CirclFi does not provide target buy prices or price alerts. However, our 13 active models produce fair value estimates ranging from $27.09 to $547.31. At $182.18, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for MRSH.

View MRSH Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →